Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "Inke"

212 News Found

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
News | June 30, 2023

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully


Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University
Digitisation | June 09, 2023

Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University

Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration


Lonza acquires biotech firm Synaffix
News | June 02, 2023

Lonza acquires biotech firm Synaffix

Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology


We need to focus on quality and affordable manufacturing: Mandaviya
Policy | May 29, 2023

We need to focus on quality and affordable manufacturing: Mandaviya

Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities


Health Minister Mandaviya inaugurates 8th International Conference on Pharma and Medical Device Sector
Policy | May 27, 2023

Health Minister Mandaviya inaugurates 8th International Conference on Pharma and Medical Device Sector

Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector


Brain Cells are starved of energy when autophagy malfunctions: New Study
News | May 05, 2023

Brain Cells are starved of energy when autophagy malfunctions: New Study

The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments


Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
News | April 28, 2023

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects


Biocon approves NCD issue
News | April 27, 2023

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.


Aurisco expands Oligonucleotide capacity
News | April 24, 2023

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.